Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia TARRYTOWN, N.Y., March 11, 2024 -- Regeneron Pharmaceuticals, Inc. announced the...

Related Keywords

Brazil ,Canada ,Switzerland ,Japan ,Maryp Mcgowan ,Mark Hudson ,Regeneron Velocimmune ,Mary Heather ,Georged Yancopoulos ,Exchange Commission ,Nasdaq ,Family Heart Foundation ,European Union ,Us Food Drug Administration ,Linkedin ,Velocimmune Technology ,Regeneron Pharmaceuticals Inc ,Regeneron Genetics Center ,Drug Administration ,Chief Medical Officer ,Family Heart ,Confidence Interval ,Chief Scientific Officer ,Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Markets ,